[
  {
    "ts": null,
    "headline": "Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?",
    "summary": "The choice isn't that hard.",
    "url": "https://finnhub.io/api/news?id=a8af284871564c61346407f68bbaded483b42ea25a1d960253ebf3a8f8fd8952",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768586760,
      "headline": "Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?",
      "id": 138155332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The choice isn't that hard.",
      "url": "https://finnhub.io/api/news?id=a8af284871564c61346407f68bbaded483b42ea25a1d960253ebf3a8f8fd8952"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus",
    "summary": "Novo Nordisk Rallies After Early U.S. Demand Signals for Wegovy Pill.",
    "url": "https://finnhub.io/api/news?id=5bb60eb483ba99d97d2adb5bd3743443357422d19f79265045c511c776c84f96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768586391,
      "headline": "Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus",
      "id": 138155333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk Rallies After Early U.S. Demand Signals for Wegovy Pill.",
      "url": "https://finnhub.io/api/news?id=5bb60eb483ba99d97d2adb5bd3743443357422d19f79265045c511c776c84f96"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer",
    "summary": "We recently published 10 Stocks Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer talked about. Pharma giant Novo Nordisk A/S (NYSE:NVO) created quite the buzz last month after its weight loss pill secured approval from the Food and Drug Administration (FDA), following which the shares jumped by […]",
    "url": "https://finnhub.io/api/news?id=5ec747533f10d21ddbfe25f2a27074c40c62fff1cbb9ee8417b02fac550588b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768585615,
      "headline": "Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer",
      "id": 138153980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer talked about. Pharma giant Novo Nordisk A/S (NYSE:NVO) created quite the buzz last month after its weight loss pill secured approval from the Food and Drug Administration (FDA), following which the shares jumped by […]",
      "url": "https://finnhub.io/api/news?id=5ec747533f10d21ddbfe25f2a27074c40c62fff1cbb9ee8417b02fac550588b1"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Structure Therapeutics: “I Don’t Want to Touch It”",
    "summary": "Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented: “Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to […]",
    "url": "https://finnhub.io/api/news?id=072213859478133446859489e1cc0eaccc1adc10479682a8c9970abba7b24054",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768583605,
      "headline": "Jim Cramer on Structure Therapeutics: “I Don’t Want to Touch It”",
      "id": 138153981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented: “Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to […]",
      "url": "https://finnhub.io/api/news?id=072213859478133446859489e1cc0eaccc1adc10479682a8c9970abba7b24054"
    }
  },
  {
    "ts": null,
    "headline": "Novo's Wegovy Pill Is Following In Zepbound's Footsteps — And It's Only Been One Week",
    "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
    "url": "https://finnhub.io/api/news?id=21826a80395f24e031e6842e0c9af5ec966a47d2bdcc510f164895cb0c958435",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768582098,
      "headline": "Novo's Wegovy Pill Is Following In Zepbound's Footsteps — And It's Only Been One Week",
      "id": 138153982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
      "url": "https://finnhub.io/api/news?id=21826a80395f24e031e6842e0c9af5ec966a47d2bdcc510f164895cb0c958435"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Wegovy Weight Loss Pill Has a Strong Launch—and Other Reasons the Stock Is Rising",
    "summary": "Novo Nordisk  traded higher in the U.S. following a string of wins for the drugmaker’s star weight-loss treatment, Wegovy.  The U.K.’s healthcare regulator said Friday that it had approved a higher dose of semaglutide, which sold under the brand name Wegovy for weight loss.  The maximum dose of up to 7.2 milligrams per week is a significant step up from the former 2.4 mg limit.",
    "url": "https://finnhub.io/api/news?id=7ef344007ad7129999848e424cb543e7c21c6253af6e5f50740a0873840f946b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768580340,
      "headline": "Novo Nordisk’s Wegovy Weight Loss Pill Has a Strong Launch—and Other Reasons the Stock Is Rising",
      "id": 138153983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk  traded higher in the U.S. following a string of wins for the drugmaker’s star weight-loss treatment, Wegovy.  The U.K.’s healthcare regulator said Friday that it had approved a higher dose of semaglutide, which sold under the brand name Wegovy for weight loss.  The maximum dose of up to 7.2 milligrams per week is a significant step up from the former 2.4 mg limit.",
      "url": "https://finnhub.io/api/news?id=7ef344007ad7129999848e424cb543e7c21c6253af6e5f50740a0873840f946b"
    }
  },
  {
    "ts": null,
    "headline": "LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling",
    "summary": "Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.",
    "url": "https://finnhub.io/api/news?id=5c2fd8c3f452e620c1d81fe313898bfa82fbc2b978b429722d56040d7023fed8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768578420,
      "headline": "LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling",
      "id": 138153984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.",
      "url": "https://finnhub.io/api/news?id=5c2fd8c3f452e620c1d81fe313898bfa82fbc2b978b429722d56040d7023fed8"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s New Prescription Plan vs. Mark Cuban’s: Experts Weigh In",
    "summary": "Fed up with soaring prescription drug costs, billionaire Mark Cuban launched the Mark Cuban CostPlus Drug Company, an online pharmacy offering low-cost generic medications, with co-founder Alex...",
    "url": "https://finnhub.io/api/news?id=979f36c7df29fb17489890c9e2296ec3d4ca920b289a7bee24012f68dfc68811",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768577329,
      "headline": "Trump’s New Prescription Plan vs. Mark Cuban’s: Experts Weigh In",
      "id": 138152502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Fed up with soaring prescription drug costs, billionaire Mark Cuban launched the Mark Cuban CostPlus Drug Company, an online pharmacy offering low-cost generic medications, with co-founder Alex...",
      "url": "https://finnhub.io/api/news?id=979f36c7df29fb17489890c9e2296ec3d4ca920b289a7bee24012f68dfc68811"
    }
  },
  {
    "ts": null,
    "headline": "Novo shares jump on 'encouraging' Wegovy pill scripts data, analysts say",
    "summary": "STORY: Novo Nordisk shares rose over 5% on Friday to highs last seen in October.Investors bought in on what analysts called 'encouraging' early U.S. data for its Wegovy pill.The weight-loss giant hopes the pill will help it regain ground in the obesity drug race.It was made available to U.S. patients from January 5 after gaining approval from regulators last month.The market is closely watching early sales for signs of strength or weakness.And investors want to see how Novo uses its first-to-market lead against rival Eli Lilly.It's positive news for Novo CEO Mike Doustdar, who took over last year.He wants to attract new consumers with the pill.Novo aims to recover from a challenging last year of profit warnings and sliding shares.Investors sold off in 2025 when sales growth of Novo's injectable medication slowed.",
    "url": "https://finnhub.io/api/news?id=9e1efd056f1c3031414d6bd52b68634ec4e2be8525e2432f0b5755e95e3325ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768576964,
      "headline": "Novo shares jump on 'encouraging' Wegovy pill scripts data, analysts say",
      "id": 138152503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk shares rose over 5% on Friday to highs last seen in October.Investors bought in on what analysts called 'encouraging' early U.S. data for its Wegovy pill.The weight-loss giant hopes the pill will help it regain ground in the obesity drug race.It was made available to U.S. patients from January 5 after gaining approval from regulators last month.The market is closely watching early sales for signs of strength or weakness.And investors want to see how Novo uses its first-to-market lead against rival Eli Lilly.It's positive news for Novo CEO Mike Doustdar, who took over last year.He wants to attract new consumers with the pill.Novo aims to recover from a challenging last year of profit warnings and sliding shares.Investors sold off in 2025 when sales growth of Novo's injectable medication slowed.",
      "url": "https://finnhub.io/api/news?id=9e1efd056f1c3031414d6bd52b68634ec4e2be8525e2432f0b5755e95e3325ed"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.",
    "summary": "The high-powered duo is teaming up to build and equip a $1 billion research facility in California.",
    "url": "https://finnhub.io/api/news?id=1d8031c81d89b5779c026c7a9e65378d6714eddffed0703ee0e9b8fb64b11992",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768575900,
      "headline": "Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.",
      "id": 138152446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The high-powered duo is teaming up to build and equip a $1 billion research facility in California.",
      "url": "https://finnhub.io/api/news?id=1d8031c81d89b5779c026c7a9e65378d6714eddffed0703ee0e9b8fb64b11992"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Friday: J.B. Hunt, PNC, Verizon",
    "summary": "↘️ J.B. Hunt Transport Services (JBHT): The logistics company recorded lower quarterly revenue, as transcontinental load volumes declined. Shares fell in off-hours trading. ? M&T Bank (MTB), PNC Financial Services (PNC) and State Street (STT) are due to report results Friday.",
    "url": "https://finnhub.io/api/news?id=e33288159a9534d4b6d99b644dc2cdc6f678fd815b2245c0e975aa4f06db6d55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768555607,
      "headline": "Stocks to Watch Friday: J.B. Hunt, PNC, Verizon",
      "id": 138149641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↘️ J.B. Hunt Transport Services (JBHT): The logistics company recorded lower quarterly revenue, as transcontinental load volumes declined. Shares fell in off-hours trading. ? M&T Bank (MTB), PNC Financial Services (PNC) and State Street (STT) are due to report results Friday.",
      "url": "https://finnhub.io/api/news?id=e33288159a9534d4b6d99b644dc2cdc6f678fd815b2245c0e975aa4f06db6d55"
    }
  },
  {
    "ts": null,
    "headline": "Why A 'Solid' First Week For Oral Wegovy Bodes Well For Novo And Lilly",
    "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
    "url": "https://finnhub.io/api/news?id=67a80304dd048920163b88a4c8cedf5ceaabf8d0bc3a33851971aee3c95ec60f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768574016,
      "headline": "Why A 'Solid' First Week For Oral Wegovy Bodes Well For Novo And Lilly",
      "id": 138152506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo Nordisk stock jumped.",
      "url": "https://finnhub.io/api/news?id=67a80304dd048920163b88a4c8cedf5ceaabf8d0bc3a33851971aee3c95ec60f"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=babaf668a9b1ae2b9f645fde1b10fec35f56d947c433db5fcee8bad86cdbcf20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768572008,
      "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know",
      "id": 138152507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=babaf668a9b1ae2b9f645fde1b10fec35f56d947c433db5fcee8bad86cdbcf20"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Techs Rise, AMD Eyes Buy Point In Powerful Week",
    "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
    "url": "https://finnhub.io/api/news?id=30121a549b5fab7b4b08c844cd7532c446dca6ce1a9c62acac3a05b515c8d4fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768568361,
      "headline": "Dow Jones Futures: Techs Rise, AMD Eyes Buy Point In Powerful Week",
      "id": 138151613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
      "url": "https://finnhub.io/api/news?id=30121a549b5fab7b4b08c844cd7532c446dca6ce1a9c62acac3a05b515c8d4fc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss",
    "summary": "Novo Nordisk  traded higher in the U.S. after the U.K.’s healthcare regulator approved a higher dose of Novo’s blockbuster weight-loss drug, Wegovy.  The Medicines and Healthcare Products Regulatory Agency said Friday that it had approved a maximum dose of up to 7.2 milligrams per week of semaglutide, a step up from the former 2.4 mg limit.  The dose is to be administered as three separate injections, strictly in adult patients with obesity.",
    "url": "https://finnhub.io/api/news?id=3bf61dc1c7713f53ebe28c24c8cac1d2a0c4ad3e9e878300dfc74e7a7cba8c0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768567020,
      "headline": "Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss",
      "id": 138151696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk  traded higher in the U.S. after the U.K.’s healthcare regulator approved a higher dose of Novo’s blockbuster weight-loss drug, Wegovy.  The Medicines and Healthcare Products Regulatory Agency said Friday that it had approved a maximum dose of up to 7.2 milligrams per week of semaglutide, a step up from the former 2.4 mg limit.  The dose is to be administered as three separate injections, strictly in adult patients with obesity.",
      "url": "https://finnhub.io/api/news?id=3bf61dc1c7713f53ebe28c24c8cac1d2a0c4ad3e9e878300dfc74e7a7cba8c0b"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Rise, Techs Lead; AMD Eyes Buy Point In Powerful Week",
    "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
    "url": "https://finnhub.io/api/news?id=47cc2a099582f57c6e1e8802bfe52e31b0f32dd6a497c0768574ee77ce6fb96f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768564147,
      "headline": "Dow Jones Futures Rise, Techs Lead; AMD Eyes Buy Point In Powerful Week",
      "id": 138150959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Techs lead futures Friday but after Thursday's market fade. AMD is eyeing an early buy point again on Taiwan Semiconductor optimism.",
      "url": "https://finnhub.io/api/news?id=47cc2a099582f57c6e1e8802bfe52e31b0f32dd6a497c0768574ee77ce6fb96f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch",
    "summary": "The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the obesity drug space.",
    "url": "https://finnhub.io/api/news?id=70bd0412af7defc379e41dc554e5ca2039fe5d0b8f2e316a05a996d430b85a98",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768563021,
      "headline": "Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch",
      "id": 138153446,
      "image": "https://image.cnbcfm.com/api/v1/image/108253253-1768511651216-gettyimages-2255813292-WEGOVY_PILLS.jpeg?v=1768511698&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the obesity drug space. ",
      "url": "https://finnhub.io/api/news?id=70bd0412af7defc379e41dc554e5ca2039fe5d0b8f2e316a05a996d430b85a98"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Exceptional 2025, But Rising Headwinds Loom In 2026",
    "summary": "Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.",
    "url": "https://finnhub.io/api/news?id=73fd2df60a0e82cd5354197ef1670ba2c95bc8959f5eabe74e8891d2a4d145ff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768559484,
      "headline": "Eli Lilly: Exceptional 2025, But Rising Headwinds Loom In 2026",
      "id": 138152378,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284860965/image_1284860965.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.",
      "url": "https://finnhub.io/api/news?id=73fd2df60a0e82cd5354197ef1670ba2c95bc8959f5eabe74e8891d2a4d145ff"
    }
  },
  {
    "ts": null,
    "headline": "3 Unstoppable Stocks to Buy in 2026 and Hold Forever",
    "summary": "These stocks are leaders in their respective industries, and they have excellent fundamentals.",
    "url": "https://finnhub.io/api/news?id=bdd8e9f61aafa4ddb273d6705df41b4a8db1f26986740062de4e2270c97b3b22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768521900,
      "headline": "3 Unstoppable Stocks to Buy in 2026 and Hold Forever",
      "id": 138143039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These stocks are leaders in their respective industries, and they have excellent fundamentals.",
      "url": "https://finnhub.io/api/news?id=bdd8e9f61aafa4ddb273d6705df41b4a8db1f26986740062de4e2270c97b3b22"
    }
  }
]